Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

E. Gobbini

h-index 18 View on Semantic Scholar

We have 3 of 90 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non–Small Cell Lung Cancer

Abstract Non–small cell lung cancer (NSCLC) is responsible for the majority of cancer-related mortality worldwide. Lung adenocarcinoma is the most common NSCLC subtype. Despite advances in targeted therapies, treatment resistance remains a critical challenge. Ribonucleotide reductase (RNR), a crucial enzyme in deoxyrib...

Utsav Sen, Dalia Natour, Subhamoy Chakraborty et al. · 0 citations
Review Sep 2026

Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer.

This review addresses the limitations of currently used biomarkers across lung cancer histologies and describes emerging immune-related biomarkers encompassing innate immune infiltration, antigen presentation capacity, cytotoxic T-cell activation, and inflammatory signaling that have shown promise as histology-independ...

E. Gobbini, Subhamoy Chakraborty, I. Vathiotis et al. · 0 citations
Open access Aug 2026

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

This study showed no OS gain in second-line treatment among patients pretreated with immunotherapy compared with those who received chemotherapy alone as first-line treatment.

E. Gobbini, M. H. Diallo, C. Clément-Duchêne et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.